{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:53:02Z","timestamp":1790139182016,"version":"4.0.1"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Teclistamab, the first approved B\u2010cell maturation antigen\u2010directed bispecific antibody for treatment of triple\u2010class exposed relapsed\/refractory multiple myeloma, demonstrated deep, durable responses with a manageable safety profile in the pivotal MajesTEC\u20101 cohort (NCT03145181\/NCT04557098). Efficacy, safety, and pharmacokinetics from the MajesTEC\u20101 China cohort are reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients received teclistamab 1.5 mg\/kg subcutaneously weekly after step\u2010up dosing; patients could switch to less frequent dosing with continued response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the China cohort (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a026; median age, 66 years; median prior lines of therapy, 5) 15\u2010month median follow\u2010up, overall response rates, very good partial response or better, and complete response or better (\u2265CR) were 76.9%, 76.9%, and 57.7%, respectively. Median time to first response and \u2265CR were 1.4 and 6.3 months, respectively; among patients with \u2265CR and have available MRD samples, MRD negativity was achieved in 14\/15 (93.3%) patients. Median duration of response, progression\u2010free survival, and overall survival were not reached; 12\u2010month duration of response, progression\u2010free survival, and overall survival rates were 78.5%, 68.0%, and 83.5%, respectively. The safety profile was consistent with the pivotal cohort. Although infections occurred in 96.2% of patients, incidence decreased over time with six patients experiencing infections for &gt;12 to 18 months. There were no discontinuations because of adverse events and no dose reductions. Ten patients switched to less frequent dosing. Teclistamab serum concentrations were consistent with the pivotal cohort, with a slightly lower mean pharmacokinetics profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Teclistamab demonstrated efficacy and safety profiles in the China cohort consistent with the pivotal cohort, supporting teclistamab as a promising treatment option for triple\u2010class exposed relapsed\/refractory multiple myeloma in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.35665","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T13:52:48Z","timestamp":1733925168000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed\/refractory multiple myeloma from the China cohort of MajesTEC\u20101"],"prefix":"10.1002","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-3804","authenticated-orcid":false,"given":"Zhen","family":"Cai","sequence":"first","affiliation":[{"name":"First Affiliated Hospital Zhejiang University College of Medicine  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Xia","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai\u2010Li","family":"He","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Xi\u2019an Jiaotong University  Xi\u2019an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Jun","family":"Dong","sequence":"additional","affiliation":[{"name":"Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liao","sequence":"additional","affiliation":[{"name":"Shengjing Hospital of China Medical University  Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Song MM","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Uhlar","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Chastain","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latisha","family":"Watkins","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchao","family":"Luo","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Huang","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuolu","family":"Niu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia A.","family":"Quijano Card\u00e9","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Guo","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Xu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca I.","family":"Verona","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Li","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Fu","sequence":"additional","affiliation":[{"name":"Myeloma &amp; Lymphoma Center Shanghai Changzheng Hospital Naval Medical University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[{"name":"West China Hospital Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-4007","authenticated-orcid":false,"given":"Juan","family":"Du","sequence":"additional","affiliation":[{"name":"Myeloma &amp; Lymphoma Center Shanghai Changzheng Hospital Naval Medical University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0023"},{"key":"e_1_2_10_3_1","unstructured":"International Agency for Research on Cancer (IARC) World Health Organization (WHO).Global Cancer Observatory: Cancer Today [Online Database]. Accessed 3 March 2024.https:\/\/gco.iarc.fr\/today\/"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010019\u20100807\u20105"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01513"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002108"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201010\u2010116129"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.356"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001531\u20102"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201004\u2010403733"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201006\u2010740944"},{"key":"e_1_2_10_13_1","unstructured":"Antengene Announces NDA Approval by NMPA for XPOVIO\u00ae China's First XPO1 inhibitor for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma. Accessed June 20 2024.https:\/\/www.antengene.com\/newsinfo\/65#:~:text=Antengene%20Corporation%20Limited%20%28the%20%E2%80%9CCompany%E2%80%9D%20or%20%E2%80%9CAntengene%E2%80%9D%29%20is an%20immunomodulatory%20agent%20and%20an%20anti\u2010CD38%20monoclonal%20antibody"},{"key":"e_1_2_10_14_1","unstructured":"Equecabtagene autoleucel injection approved with conditions by China NMPA. Accessed June 20 2024.https:\/\/english.nmpa.gov.cn\/2023\u201006\/30\/c_940315.htm"},{"key":"e_1_2_10_15_1","unstructured":"Carsgen Therapeutics.NMPA approves the NDA for CARsgen's BCMA CAR\u2010T therapy zevorcabtagene autoleucel for relapsed or refractory multiple myeloma. Accessed March 11 2024.https:\/\/www.carsgen.com\/en\/news\/20240301\/"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010022\u201002305\u20104"},{"key":"e_1_2_10_17_1","unstructured":"What is Equecabtagene Autoleucel used for?Accessed June 20 2024.https:\/\/synapse.patsnap.com\/article\/what\u2010is\u2010equecabtagene\u2010autoleucel\u2010used\u2010for"},{"key":"e_1_2_10_18_1","unstructured":"TECVAYLI.Summary of product characteristics.Janssen Biologics. Accessed October 26 2022.https:\/\/ema.europa.eu\/en\/documents\/product\u2010information\/tecvayli\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","unstructured":"TECVAYLI\u00ae (teclistamab\u2010cqyv) injection for subcutaneous use.Prescribing information. Janssen Oncology. Accessed February 10 2023.https:\/\/janssenlabels.com\/package\u2010insert\/product\u2010monograph\/prescribing\u2010information\/TECVAYLI\u2010pi.pdf","DOI":"10.1097\/01.COT.0000920700.02106.a7"},{"key":"e_1_2_10_20_1","unstructured":"ELREXFIO\u2010 elranatamab\u2010bcmm injection solution.Highlights of prescribing information. Accessed November 17 2023.https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19669"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","unstructured":"GarfallAL NookaAK vandeDonkNWCJ et al.Long\u2010term follow\u2010up from the phase 1\/2 MajesTEC\u20101 trial of teclistamab in patients with relapsed\/refractory multiple myeloma.American Society of Clinical Oncology (ASCO) Annual Meeting; May 31\u2013June 4 2024; Poster #7540.","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8011"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01338\u20106"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30206\u20106"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523\u2010022\u201000904\u2010y"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523\u2010022\u201000893\u2010y"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523\u2010023\u201000989\u2010z"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.38961"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006178"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(21)00283\u20100"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117176"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35107"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(23)00159\u20106"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000879\u20107"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.016"},{"key":"e_1_2_10_38_1","unstructured":"TanCRAS BrunaldiL PopatR et al.Real\u2010world evaluation of teclistamab for the treatment of relapsed\/refractory mutliple myeloma (RRMM).American Society of Hematology (ASH) Annual Meeting; December 9\u201312 2023; Poster #3347"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011658"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643\u20103230.BCD\u201023\u20100049"},{"key":"e_1_2_10_41_1","unstructured":"NiuZLJ LiJ Quijano Card\u00e9NA et al.Pharmacokinetic and immunogenicity results from the China cohort of the MajesTEC\u20101 study of teclistamab for relapsed\/refractory multiple myeloma.American College of Clinical Pharmacology (ACCP) Annual Meeting; September 8\u201310 2024; Poster #107."},{"key":"e_1_2_10_42_1","unstructured":"TECVAYLI Injection.Product information.Johnson & Johnson Pharmaceutical Ltd. Accessed August 20 2024.https:\/\/www.xian\u2010janssen.com.cn\/sites\/default\/files\/PDF\/%E7%89%B9%E7%AB%8B"},{"key":"e_1_2_10_43_1","unstructured":"Johnson & Johnson.TECVAYLI\u00ae(teclistamab\u2010cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma. Accessed March 28 2024.https:\/\/www.jnj.com\/media\u2010center\/press\u2010releases\/tecvayli\u2010teclistamab\u2010cqyv\u2010biweekly\u2010dosing\u2010approved\u2010by\u2010the\u2010u\u2010s\u2010fda\u2010for\u2010the\u2010treatment\u2010of\u2010patients\u2010with\u2010relapsed\u2010or\u2010refractory\u2010multiple\u2010myeloma"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:59:04Z","timestamp":1760266744000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/cncr.35665"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35665","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"2024-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e35665"}}